Marvel Biosciences Corp. (TSXV:MRVL)

Market Cap	8.47M
Revenue (ttm)	n/a
Net Income (ttm)	-1.61M
Shares Out	52.95M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,000
Average Volume	58,835
Open	0.1650
Previous Close	0.1600
Day's Range	0.1600 - 0.1750
52-Week Range	0.0750 - 0.1800
Beta	0.82
RSI	66.37
Earnings Date	Jun 18, 2025

About Marvel Biosciences

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Ca...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: J. Matheson
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MRVL